Drug intelligence / Profile preview

pseudoephedrine + triprolidine (Combiphar)

Development stage
Unknown
Lead developer
Combiphar
Modality
Small Molecules
Administration
Oral
01

Overview

Comtusi Pilek & Alergi is a combination pharmaceutical product developed by Combiphar for the symptomatic relief of cold symptoms and nasal respiratory allergies, such as nasal congestion, sneezing, and rhinorrhea. It is formulated as an oral syrup containing the first-generation antihistamine triprolidine hydrochloride and the sympathomimetic decongestant pseudoephedrine hydrochloride. Triprolidine acts as an antagonist at the histamine H1 receptor to alleviate allergic symptoms like sneezing and runny nose, while pseudoephedrine acts as an agonist at alpha-adrenergic receptors to induce vasoconstriction in the nasal mucosa, thereby reducing swelling and relieving nasal congestion.

Brand names
Comtusi Pilek & AlergiComtusi Pilek dan Alergi
Other names
pseudoephedrine + triprolidinepseudoephedrine hydrochloride + triprolidine hydrochloridetriprolidine + pseudoephedrinetriprolidine hydrochloride + pseudoephedrine hydrochloride
02

Targets

HRH1 (Histamine H1 Receptor)ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)

Beyond the preview

Go deeper on pseudoephedrine + triprolidine (Combiphar).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pseudoephedrine + triprolidine (Combiphar).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call